[1] |
Oh DD, Zhao CY, Murrell DF. A review of case⁃control studies on the risk factors for the development of autoimmune blistering diseases[J]. J Eur Acad Dermatol Venereol, 2016,30(4):595⁃603. doi: 10.1111/jdv.13386.
|
[2] |
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020,395(10223):497⁃506. doi: 10.1016/S0140⁃6736(20)30183⁃5.
|
[3] |
England BR, Roul P, Yang Y, et al. Risk of COVID⁃19 in rheumatoid arthritis: a national veterans affairs matched cohort study in at⁃risk individuals[J]. Arthritis Rheumatol, 2021,73(12):2179⁃2188. doi: 10.1002/art.41800.
|
[4] |
中国疾病预防控制中心. 全国新型冠状病毒感染疫情情况[EB/OL]. [2023⁃04⁃05]. https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202304/t20230401_264798.html.
|
[5] |
Yang W, Yang S, Wang L, et al. Clinical characteristics of 310 SARS⁃CoV⁃2 Omicron variant patients and comparison with Delta and Beta variant patients in China[J]. Virol Sin, 2022,37(5):704⁃715. doi: 10.1016/j.virs.2022.07.014.
|
[6] |
Wu Q, Wang H, Cai J, et al. Vaccination effects on post⁃infection outcomes in the Omicron BA.2 outbreak in Shanghai[J]. Emerg Microbes Infect, 2023,12(1):e2169197. doi: 10. 1080/22221751.2023.2169197.
|
[7] |
Zhang X, Zhang W, Chen S. Shanghai′s life⁃saving efforts against the current omicron wave of the COVID⁃19 pandemic[J]. Lancet, 2022,399(10340):2011⁃2012. doi: 10.1016/S0140⁃6736(22)00838⁃8.
|
[8] |
Webster HH, Nyberg T, Sinnathamby MA, et al. Hospitalisation and mortality risk of SARS⁃COV⁃2 variant omicron sub⁃lineage BA.2 compared to BA.1 in England[J]. Nat Commun, 2022,13(1):6053. doi: 10.1038/s41467⁃022⁃33740⁃9.
|
[9] |
Kasperkiewicz M, Schmidt E, Fairley JA, et al. Expert recommendations for the management of autoimmune bullous diseases during the COVID⁃19 pandemic[J]. J Eur Acad Dermatol Venereol, 2020,34(7):e302⁃e303. doi: 10.1111/jdv. 16525.
|
[10] |
Arleo T, Tong D, Shabto J, et al. Clinical course and outcomes of COVID⁃19 in rheumatic disease patients: a case cohort study with a diverse population[J]. Clin Rheumatol, 2021,40(7):2633⁃2642. doi: 10.1007/s10067⁃021⁃05578⁃x.
|
[11] |
Moghadam FS, Kianfar N, Dasdar S, et al. Adverse outcome and severity of COVID⁃19 in patients with autoimmune bullous diseases: a historical cohort study[J]. Dermatol Ther, 2022,35(9):e15672. doi: 10.1111/dth.15672.
|
[12] |
Parasher A. COVID⁃19: current understanding of its patho⁃physiology, clinical presentation and treatment[J]. Postgrad Med J, 2021,97(1147):312⁃320. doi: 10.1136/postgradmedj⁃2020⁃138577.
|
[13] |
中国医疗保健国际交流促进会皮肤科分会. 寻常型天疱疮诊断和治疗专家建议(2020)[J]. 中华皮肤科杂志, 2020,53(1):1⁃7. doi: 10.35541/cjd.20190703.
|
[14] |
中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会. 自身免疫性表皮下大疱病诊疗共识(2022)[J]. 中华皮肤科杂志, 2022,55(1):1⁃11. doi: 10.35541/cjd.20210532.
|
[15] |
Ochani R, Asad A, Yasmin F, et al. COVID⁃19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management[J]. Infez Med, 2021,29(1):20⁃36.
|
[16] |
Raman R, Patel KJ, Ranjan K. COVID⁃19: unmasking emerging SARS⁃CoV⁃2 variants, vaccines and therapeutic strategies[J]. Biomolecules, 2021,11(7):993. doi: 10.3390/biom11070993.
|
[17] |
Colnago M, Benvenuto GA, Casaca W, et al. Risk factors associated with mortality in hospitalized patients with COVID⁃19 during the Omicron wave in Brazil[J]. Bioengineering (Basel), 2022,9(10):584. doi: 10.3390/bioengineering9100584.
|
[18] |
陈波, 费宇, 李玟, 等. 重症新型冠状病毒肺炎患者死亡风险因素研究[J]. 现代预防医学, 2022,49(15):2856⁃2860. doi: 10.20043/j.cnki.MPM.202201321.
|
[19] |
Chuenkitmongkol S, Solante R, Burhan E, et al. Expert review on global real⁃world vaccine effectiveness against SARS⁃CoV⁃2[J]. Expert Rev Vaccines, 2022,21(9):1255⁃1268. doi: 10.1080/ 14760584.2022.2092472.
|
[20] |
Kridin K, Schonmann Y, Weinstein O, et al. The risk of COVID⁃19 in patients with bullous pemphigoid and pemphigus: a population⁃based cohort study[J]. J Am Acad Dermatol, 2021,85(1):79⁃87. doi: 10.1016/j.jaad.2021.02.087.
|
[21] |
Joly P. Incidence and severity of COVID⁃19 in patients with autoimmune blistering skin diseases: a nationwide study[J]. J Am Acad Dermatol, 2022,86(2):494⁃497. doi: 10.1016/j.jaad. 2021.10.034.
|